PubMed HealthSearch

PubMed · 7937143

Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms.

Abstract

A new method for typing single nucleotide polymorphisms in DNA is described. In this method, specific fragments of genomic DNA containing the polymorphic site(s) are first amplified by the polymerase chain reaction (PCR) using one regular and one phosphorothioate-modified primer. The double-stranded PCR product is rendered single-stranded by treatment with the enzyme T7 gene 6 exonuclease, and captured onto individual wells of a 96 well polystyrene plate by hybridization to an immobilized oligonucleotide primer. This primer is designed to hybridize to the single-stranded target DNA immediately adjacent from the polymorphic site of interest. Using the Klenow fragment of E. coli DNA polymerase I or the modified T7 DNA polymerase (Sequenase), the 3' end of the capture oligonucleotide is extended by one base using a mixture of one biotin-labeled, one fluorescein-labeled, and two unlabeled dideoxynucleoside triphosphates. Antibody conjugates of alkaline phosphatase and horseradish peroxidase are then used to determine the nature of the extended base in an ELISA format. This paper describes biochemical features of this method in detail. A semi-automated version of the method, which we call Genetic Bit Analysis (GBA), is being used on a large scale for the parentage verification of thoroughbred horses using a predetermined set of 26 diallelic polymorphisms in the equine genome.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T T Nikiforov, R B Rendle, P Goelet, Y H Rogers, M L Kotewicz, S Anderson, G L Trainor, M R Knapp. 1994-10-11. Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms.. https://doi.org/10.1093/nar%2F22.20.4167

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Evaluation and interference study of hemoglobin A1c measured by turbidimetric inhibition immunoassay.

The technical performance of the turbidimetric immunoinhibition (TI) assay for hemoglobin (Hb) A1c (Tina-quant Hb A1c, Boehringer Mannheim, Indianapolis, Ind) was evaluated by using the BM/Hitachi 911 analyzer. Intra-assay imprecision was less than 2.7%, and interassay imprecision was less than 2.8% as measured by coefficient of variation. In 93 subjects with diabetes who did not have hemoglobin variants, results of the TI assay for Hb A1c correlated strongly with those obtained by using a high-performance liquid chromatography analyzer (Diamat, BioRad Laboratories, Hercules, Calif). Among 241 subjects who had or did not have hemoglobin variants, the TI assay for Hb A1c correlated strongly with results of affinity chromatography for total glycated hemoglobin (Glyc-Affin GHb, IsoLab, Akron, Ohio). We also studied the effect of various percentages of hemoglobin S, C, E, and F on the accuracy of the TI Hb A1c assay. Only high hemoglobin F percentages caused interference. More than 14 times as many samples can be analyzed per hour by using the TI Hb A1c assay than can be analyzed by using the HPLC assay. For high-volume reference laboratories, using the fully automated TI Hb A1c assay to monitor glycemic control in patients with diabetes may be preferable to using the conventional ion-exchange high-performance liquid chromatography Hb A1c assay because the TI assay measures Hb A1c more accurately in patients with diabetes who have hemoglobin variants, and it requires less time.

Autoanalysis

Effect of terminal renal failure on the ratio of free to total prostate-specific antigen.

OBJECTIVES: To evaluate the effect of terminal renal failure on the ratio of free to total prostate-specific antigen (PSA). METHODS: We measured free and total PSA in a group of 48 men on chronic hemodialysis. Samples were taken before dialysis and compared with a control group of 101 men without known prostatic or renal disease. Measurements of total and free PSA were made simultaneously with an ES-300 analyzer from Boehringer Mannheim according to the manufacturer's instructions. RESULTS: Patients on hemodialysis have lower complexed PSA but higher free PSA than controls. Therefore, we observed a markedly higher calculated proportion of free PSA in the dialysis group (0.54 +/- 0.16 vs. 0.33 +/- 0.14, p < 0.00001). The calculated proportion of free PSA decreases progressively as the levels of total PSA increases from 0 to 4 microg/l in both groups. By multivariate analysis, total PSA (p < 0.00001) and dialysis (p < 0.00001) were independent predictors of the fraction of free PSA. Age had no significant effect after correction for total PSA (p = 0.23). CONCLUSION: Patients on hemodialysis have normal total PSA but a significantly higher proportion of free PSA. Caution is therefore recommended for the interpretation of free PSA in that population since cutoff established in patients without renal disease may be inappropriate.

Autoanalysis

Changes in the American health care system: crisis in the clinical laboratory.

American medicine is undergoing unprecedented changes, and the resulting distortions are affecting the economics, organization and operations of all clinical laboratories. Professionals who work in these laboratories are facing administrative and economic pressures to reduce costs, to increase productivity, and to comply with proliferating new statutes and regulations. The medical 'cottage industry' in which the patient was the focus of the medical professionals' attention and endeavours is being replaced by the corporate management of many health care activities in which financial profits are being given first priority. Medical facilities, including clinical laboratories, are being bought and sold, being consolidated, or simply being closed. The clinical laboratories may be at the vortex of the maelstrom affecting American medicine. Cost pressures are encouraging further automation and retraining of laboratory staffs. If the leaders in laboratory medicine are unable to accomplish the necessary tasks to meet the new challenges, there inevitably is a non-medical, non-scientific financial manager at hand who is willing to define the changes and the desired outcome. Because of the rapidity of the changes taking place, it is not possible to predict with any confidence the modifications that will achieve a permanent status or the degree to which medical professionals will remain masters of their fates. The evolving health care system will become less costly, more technologically advanced, and a more challenging system in which to work.

Autoanalysis